Fig 1.
Synthetic route of sulfonamide chalcone (2) and its precursor, N-(4-acetylphenyl)benzenesulfonamide (1).
Reagents and conditions: (a) CH2Cl2, 6 h (reflux); (b) p-nitrobenzaldehyde, EtOH, NaOH (50% w/w, ketone) 24 h (room temperature).
Table 1.
Yield, physical state, melting point, purity, and spectroscopic data (GS-MS, IR, 1H-NMR) of N-(4-acetylphenyl)benzenesulfonamide (1) and N-{4-[(E)-3-(4-nitrophenyl)prop-2-enoyl]phenyl}-benzenesulfonamide (2).
Table 2.
Means ± standard deviation (SD) of histidine revertant colonies, mutagenic index (MI), and inhibition percentage (IP) of mutagenicity for two tester strains of Salmonella typhimurium, TA98 and TA100, after treatment with different doses of sulfonamide chalcone N-{4-[3-(4-nitrophenyl)prop-2-enoyl]phenyl}-benzenesulfonamide (CPN).
Table 3.
Evaluation of cytotoxic and genotoxic activities in the bone marrow of mice treated with sulfonamide chalcone N-{4-[3-(4-nitrophenyl)prop-2-enoyl]phenyl}-benzenesulfonamide (CPN) based on MNPCE and PCE/NCE frequency.
Table 4.
Evaluation of anticytotoxic and antigenotoxic activities in the bone marrow of mice treated with sulfonamide chalcone N-{4-[3-(4-nitrophenyl)prop-2-enoyl]phenyl}-benzenesulfonamide (CPN) plus mitomycin C (MMC) based on MNPCE and PCE/NCE frequency.